Publikationen

2020

1. Gustavo Werutsky, G., et al., Locoregional recurrence risk after neoadjuvant chemotherapy: A pooled analysis of nine prospective neoadjuvant breast cancer trials. Eur J Cancer, 2020 May. 130: p. 92-101.

2. Wappenschmidt, B., et al., Criteria of the German Consortium for Hereditary Breast and Ovarian Cancer for the Classification of Germline Sequence Variants in Risk Genes for Hereditary Breast and Ovarian Cancer. Geburtshilfe Frauenheilkd, 2020 Apr. 80(4): p. 410-429.

3. Bredart, A., et al., How to facilitate psychosocial adjustment in women tested for hereditary breast or ovarian cancer susceptibility? Insights from network analysis. Psychooncology, 2020 Mar. 29(3): p. 550-556.

4. Pohl-Rescigno, E., et al., Association of Germline Variant Status With Therapy Response in High-risk Early-Stage Breast Cancer: A Secondary Analysis of the GeparOcto Randomized Clinical Trial. JAMA Oncol, 2020 Mar 12.

5. Feng, H., et al., Transcriptome-wide association study of breast cancer risk by estrogen-receptor status. Genet Epidemiol, 2020 Mar 1.

6. Yang, X., et al., Cancer Risks Associated With Germline PALB2 Pathogenic Variants: An International Study of 524 Families. J Clin Oncol, 2020 Mar 1. 38(7): p. 674-685.

7. Yang, X., et al., Ovarian and breast cancer risks associated with pathogenic variants in RAD51C and RAD51D. J Natl Cancer Inst, 2020 Feb 28.

8. Mavaddat, N., et al., Correction to: Risk-reducing salpingo-oophorectomy, natural menopause, and breast cancer risk: an international prospective cohort of BRCA1 and BRCA2 mutation carriers. Breast Cancer Res, 2020 Feb 26. 22(1): p. 25.

9. Leman, R., et al., Novel diagnostic tool for prediction of variant spliceogenicity derived from a set of 395 combined in silico/in vitro studies: an international collaborative effort. Nucleic Acids Res, 2020 Feb 20. 48(3): p. 1600-1601.

10. Engel, C., et al., Breast cancer risk in BRCA1/2 mutation carriers and noncarriers under prospective intensified surveillance. Int J Cancer, 2020 Feb 15. 146(4): p. 999-1009.

11. Patel, V.L., et al., Association of Genomic Domains in BRCA1 and BRCA2 with Prostate Cancer Risk and Aggressiveness. Cancer Res, 2020 Feb 1. 80(3): p. 624-638.

12. Li, H., et al., Alcohol Consumption, Cigarette Smoking, and Risk of Breast Cancer for BRCA1 and BRCA2 Mutation Carriers: Results from The BRCA1 and BRCA2 Cohort Consortium. Cancer Epidemiol Biomarkers Prev, 2020 Feb. 29(2): p. 368-378.

13. Puesken, M., et al., Ex Vivo Study of Artifacts Caused by Breast Tissue Markers with Different 1.5 Tesla and 3 Tesla MRI Scanners - A Bicentric Study. Acad Radiol, 2020 Jan 30.

14. Bredart, A., et al., The "Psychosocial Aspects in Hereditary Cancer" questionnaire in women attending breast cancer genetic clinics: Psychometric validation across French-, German- and Spanish-language versions. Eur J Cancer Care (Engl), 2020 Jan. 29(1): p. e13173.

15. Escala-Garcia, M., et al., A network analysis to identify mediators of germline-driven differences in breast cancer prognosis. Nat Commun, 2020 Jan 16. 11(1): p. 312.

16. Mavaddat, N., et al., Risk-reducing salpingo-oophorectomy, natural menopause, and breast cancer risk: an international prospective cohort of BRCA1 and BRCA2 mutation carriers. Breast Cancer Res, 2020 Jan 16. 22(1): p. 8.

17. Fachal, L., et al., Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes. Nat Genet, 2020 Jan. 52(1): p. 56-73.